CLINICAL_TRIALS ClinicalTrials.gov record update

Phase I/II, Open Label Study of Sequential Taxotere® (Docetaxel) and Gleevec® (Imatinib Mesylate) in Hormone Refractory Prostate Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT00861471
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:36:11.258354+00:00
Published At: 2011-06-29T00:00:00+00:00
Record Updated At: 2016-06-30
Results Posted At: 2011-06-29
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Prostate Cancer", "Prostatic Neoplasms"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2016-06-30"
protocolSection.identificationModule.nctId: "NCT00861471"
protocolSection.identificationModule.officialTitle: "Phase I/II, Open Label Study of Sequential Taxotere\u00ae (Docetaxel) and Gleevec\u00ae (Imatinib Mesylate) in Hormone Refractory Prostate Cancer"
protocolSection.statusModule.overallStatus: "TERMINATED"
protocolSection.designModule.phases: ["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2011-06-29"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.